Search - tctmd.com

Displaying 141 - 160 of 169

Sort: Relevancy | Date

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

Michael O'Riordan

January 18, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Michael O'Riordan

December 02, 2015

News Daily News

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Michael O'Riordan

December 02, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Daily News

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Todd Neale

August 17, 2015

News Daily News

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

Todd Neale

August 17, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Daily News

Las Unidades de Urgencia que realizan Bypasses Reducen el Tiempo de Reperfusión en las PCI Primarias

L.A. McKeown

July 05, 2013

News Daily News

由休克引起的死亡风险可能不会影响长期存活

L.A. McKeown

June 20, 2013

Advertisement

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Las Unidades de Urgencia que realizan Bypasses Reducen el Tiempo de Reperfusión en las PCI Primarias

由休克引起的死亡风险可能不会影响长期存活

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content